Skip to main content
. 2021 Jul 2;59(1):891–901. doi: 10.1080/13880209.2021.1944224

Figure 1.

Figure 1.

Antiproliferative effects of imatinib, dasatinib and nilotinib on the sensitive CML cell K562 and resistant CML cell K562-R. Cells were treated with different concentrations of imatinib (A), dasatinib (B) or nilotinib (C) for 48 h. The cell viability was measured using MTT assay. Data were represented as the mean ± SD obtained from three independent experiments.